EXEL vs JAZZ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
JAZZ presents a stark contradiction between fundamental health and market valuation, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits an extremely attractive valuation with a Forward P/E of 7.74 and a PEG ratio of 0.63, its internal financial health is deteriorating, evidenced by negative profit margins and ROE. Despite a massive 1-year price surge of 90.3%, bearish insider sentiment and a low technical trend score suggest a potential peak or internal instability. The stock currently functions as a high-risk value play where analyst optimism clashes with poor deterministic health metrics.
Compare Another Pair
Related Comparisons
EXEL vs JAZZ: Head-to-Head Comparison
This page compares Exelixis, Inc. (EXEL) and Jazz Pharmaceuticals plc (JAZZ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.